Background
Metabolic disorders associated with atherosclerosis and cardiovascular disease have been described in "HIV-infected" individuals. We investigated (i) whether normotensive "HIV-infected" individuals and hypertensive patients have similarities regarding their arterial elastic properties and (ii) the effect of highly active antiretroviral therapy (HAART) and metabolic factors on arterial stiffness.
methodS
In a case-control study, we compared measurements of pulse wave velocity (PWV), arterial blood pressure, and markers of metabolic profile in 56 normotensive, "HIV-infected" patients (mean age 40 ± 13 years) to 28 age-and sex-matched newly diagnosed untreated patients with hypertension and 28 healthy individuals. reSultS "HIV-infected" patients had higher PWV than healthy controls but lower PWV than hypertensives (8.1 ± 1.4 m/s vs. 6.7 ± 1.1 m/s vs.
9.0 ± 1.0 m/s, P = 0.003 and 0.01, respectively). However, patients on HAART had similar PWV with hypertensives (8.4 ± 1.4 vs. 9.0 ± 1.0 m/s P = 0.25). Patients on HAART had higher PWV than patients without (8.4 ± 1.4 m/s vs. 7.5 ± 1.3 m/s, P = 0.03). Patients on HAART had higher total cholesterol, triglycerides, and diastolic blood pressure than patient's naive to HAART (P < 0.05). In multivariate analysis, the independent determinants of increased PWV were HAART duration (unstandardized coefficient b v = 0.007, P = 0.04), serum cholesterol (b = 0.007, P = 0.04), mean or diastolic blood pressure (b = 0.049 and b = 0.060, P < 0.01).
concluSionS "HIV-infected" individuals have increased arterial stiffness compared to healthy controls. Patients on antiretroviral therapy have similarities regarding their arterial elastic properties with patients with untreated hypertension. There is an independent association between duration of antiretroviral therapy, cholesterol levels, and blood pressure with increased arterial stiffness in "HIV-infected" patients. articles "HIV-Infected" Patients and Arterial Stiffness "HIV-infected" patients on HAART appear to have a higher PWV compared to patients not receiving antiretroviral treatment. 14 A study by van Wijk et al. 15 reported that HIV-infected patients undergoing HAART presented a higher risk of cardiovascular disease, even in the absence of clustering of metabolic risk variables. The authors suggested that both HIV infection and HAART may promote atherosclerosis through mechanisms involving endothelial cells, either directly or indirectly via metabolic risk factors.
The aim of the present study was to investigate (i) whether normotensive "HIV-infected" individuals and hypertensive patients have similarities regarding their arterial elastic properties and (ii) the effect of HAART on arterial stiffness.
Study population. Our study population consisted of 56 "HIVinfected" patients (mean age 40 ± 13 years, 96% male). The median time to diagnosis of HIV infection was 42 months (interquartile range 10-120 months). Exclusion criteria were considered the presence of opportunistic infectious diseases, malignancies, renal and liver disease, diabetes, hypertension and/or use of either antihypertensive or lipid lowering regiments. According to Centers for Disease Control and Prevention classification, 14, 16 34 patients were Centers for Disease Control and Prevention class A (A1 = 6, A2 = 23, A3 = 5), 12 class B (B2 = 8, B3 = 4), and 10 class C (C2 = 1, C3 = 9). Additionally, three "HIV-infected" patients had co-infection of hepatitis C and five of hepatitis B. HAART was initiated in "HIV-infected" patients because of disease-related symptoms or because of a T lymphocyte CD4 count <340 cells/ml in asymptomatic subjects, following current treatment guidelines. 16 Thirty-four of the 56 (60%) "HIV-infected" patients were on HAART including PIs (n = 23), NNRTI (n = 22), and NRTI (n = 34) while the remaining 22 patients were naive to HAART. Demographics, data regarding the HIV infection (viral load, HAART duration, level of CD4 cells) and the treatment (regimens, duration) as well as the metabolic profile (serum glucose, lipids) and liver function biochemistry of the HIV-infected patients are outlined in Table 1 . "HIV-infected" patients were clinically stable with no evidence of infection or other HIV-related pathology at inclusion.
Following a pattern of two cases to one control, "HIVinfected" patients were matched for age and sex with 28 non-"HIV-infected" newly diagnosed, untreated hypertensive patients (positive controls). The diagnosis of arterial hypertension was defined as seated systolic blood pressure >140 mm Hg and/or diastolic pressure >90 mm Hg during at least three measurements and >125/80 mm Hg during 24-h ambulatory blood pressure monitoring. This cohort was derived from a population of 100 consecutive untreated and newly diagnosed hypertensive patients which were examined in the hypertension unit of our hospital, as previously published. 17 Furthermore, "HIV-infected" subjects were matched for age and sex, using a ratio of two cases to one control, with 28 healthy individuals who visited the outpatient clinics of our institution for a routine check-up (negative controls).
All control subjects had no history of cardiovascular disease, normal physical examination, and normal electrocardiogram and were found negative in the testing for HIV infection.
We excluded from the study those "HIV-infected" patients, hypertensive patients, and healthy subjects with serum cholesterol >6.21 mmol/l (240 mg/dl), serum triglyceride >4.52 mmol/l (400 mg/dl), diabetes or fasting glycemia >7 mmol/l (126 mg/ dl), serum creatinine >177 mmol/l (2 mg/ dl), evidence of valvular disease, coronary artery disease, peripheral artery disease, previous cerebrovascular accident, or treatment with any cardiovascular drug, or any evidence of inflammation over a period of >2 months before inclusion in the study. The study was approved by the hospital's scientific committee and all patients gave informed written consent. The research has been carried out in accordance with the Declaration of Helsinki (2000) of the World Medical Association.
Study protocol. All participants were examined at morning hours, in a quiet temperature controlled room (21-23 °C), while a resting period of 20 min was allowed for every volunteer before measurements in order to reach baseline conditions. Blood pressure measurements were performed with mercury sphygmomanometer and a cuff placed on the left arm. Three measurements were obtained and their averages were taken into account.
An established index for arterial stiffness, 10,17 the carotidfemoral PWV was assessed by measuring the pulse transit time and the distance travelled between the two recording sites (PWV (m/s) = travel distance (m)/transit time (s)). For pulse wave recording we used a validated noninvasive device (Complior SP; Artech Medical, Pantin, France) with capability of online wave recording as well as automatic PWV calculation.
A simultaneous recording was performed by two pressuresensitive transducers of two different pulse waves at the right base of the neck for the common carotid artery and over the right femoral artery. Measurement of the distance between the transducers over the body surface allowed obtaining PWV (m/s). Quality control was enhanced by visual inspection in order to eliminate any aberrant waveforms not screened out by the program. On the same day of the PWV measurement, blood samples were collected from each participant after an overnight fast for the determination of routine biochemical profile including glucose, total cholesterol, triglycerides, creatinine, alanine aninotransferase, aspartate transaminase, γ-glutamyl transpeptidase (GGT), and alkaline phosphatase. Glomerular filtration rate was calculated using the using the Cockcroft-Gault equation. All "HIV-infected" patients were clinically stable with no evidence of infection or other HIVrelated pathology during examination.
Statistical analysis. All variables were tested for homogeneity of variance and normal distribution. Skewed variables were log-transformed to normalize their distribution. Data are expressed as mean ± s.d., or median (interquartile range) where applicable. The t-test was used for the comparison of quantitative observations and the χ 2 -test was used to compare articles "HIV-Infected" Patients and Arterial Stiffness qualitative characteristics. Differences in PWV between the three study groups ("HIV-infected" patients, hypertensives, healthy controls) were examined by full factorial analysis of variance (general linear model) using as covariables BMI, smoking status, blood pressure (systolic or diastolic separately), cholesterol, triglycerides, serum glucose, creatinine, or glomerular filtration rate. Post hoc comparisons were performed with Bonferroni's correction. Differences in variables between patients with and without HAART, PI, NRTI, and NNRTI or between the above patient subgroups and controls were assessed by two-tailed unpaired t-test. Using simple linear regression the association of PWV with age, sex, BMI, atherosclerotic risk factors (blood pressure, smoking, serum cholesterol, triglycerides and glucose levels), GGT, smoking status, time since diagnosis of HIV disease, minimum CD4 lymphocyte counts and maximum viral load, current viral load, and current CD4 lymphocyte counts and duration of HAART was examined. Additionally, exposure to HAART, as well as a viral load of over 10 5 copies/ml for a period of >6 months or T lymphocyte CD4 count <200 cells/ml for 6 months were examined as dichotomous variables. The unstandardized coefficient regression b and the corresponding 95% confidence intervals and P values are reported.
We have adjusted each one of the significant univariate associations (with P < 0.05) between PWV and the examined variables separately, using a multivariable regression analysis model weighted for age and including sex, GGT, time to HIV diagnosis, viral load >10 5 copies/ml for a period of >6 months and CD4 count <200 cells/ml for >6 months. This analysis was performed to adjust the univariate associations between PWV, metabolic factors and HAART for age, sex, and markers related to disease activity. [5] [6] [7] Finally, all variables related to PWV with a P value of <0.05 in univariate analysis, as well as sex, were entered in a multivariable regression model weighted for age. Using both backward and forward procedure, the independent multivariable determinants of PWV were assessed. All covariables included in the final models were tested for interactions. The following variables were entered in the model separately to avoid colinearity (i) systolic, diastolic, or mean blood pressure; (ii) use of HAART (any regimen), PI, or NNRTI. A P value <0.05 was considered statistical significant. SPSS 13 software (SPSS, Chicago, IL) was used for analysis.
reSultS
All patients completed the study without any study-related complaint or problem. The three groups of patients had similar age, sex, and atherosclerotic risk factors except of blood pressure for the group of hypertensive patients ( Table 1) .
comparisons between hiv patients, hypertensive patients, and healthy controls Analysis of variance with additional post hoc tests indicated that "HIV-infected" patients had a higher PWV than healthy controls (P = 0.003) but a lower PWV than patients with hypertension (P = 0.01) ( Table 1 , F for the model = 21.3, P < 0.01). Differences remained significant after adjustment for blood pressure (systolic, diastolic, and mean) and risk factors. Furthermore, patients receiving HAART had higher PWV than "HIV-infected" patients without antiretroviral therapy (P = 0.03). Interestingly, patients on HAART had similar PWV values with hypertensive subjects (P = 0.25). "HIV-infected" patients without HAART had also higher PWV than healthy individuals (P = 0.03) ( Table 1 , F for the model = 11.5, P < 0.01). Similarly, patients on PI had similar PWV with hypertensives (P = 0.35) and higher than patients on other antiretroviral treatment or no treatment (P = 0.02) or controls (P < 0.01) (8.5 ± 1.4. vs. 9.0 ± 1.0 vs. 7.6 ± 1.4 vs. 6.7 ± 1.1, respectively, F for the model = 8.7, P = 0.01). Among "HIV-infected" patients, those receiving HAART had higher diastolic blood pressure cholesterol and triglyceride levels compared to patients on no treatment ( Table 1 , for all comparisons, P < 0.05). Patients receiving HAART had a higher incidence of viral load >10 5 copies/ml for >6 months (P = 0.05), lower minimum CD4 count (P < 0.01), a reduced current viral load (P < 0.01), higher GGT (P = 0.03), and similar maximum viral load, current CD4 count and time to diagnosis of HIV infection compared to patients naive to treatment ( Table 1) .
The duration of HAART treatment was also related with cholesterol and triglyceride levels (b = 0.26 (95% CI: 0.006, 0.515), P = 0.04 and b = 0.34 (95% CI: 0.014, 0.68), P < 0.01). Similarly, patients on PI had higher serum cholesterol (P < 0.01), triglycerides (P = 0.01), and diastolic arterial blood pressure (P = 0.01) in comparison with "HIV-infected" patients on other treatment or no treatment, as also previously published. 7 
determinants of Pwv among hiv patients
The univariate determinants of PWV in "HIV-infected" patients are shown in Table 2 . In univariate regression analyses, age, diastolic and mean blood pressure, cholesterol, triglyceride levels, glomerular filtration rate, use of HAART, duration of HAART, use of PI, and use of NRTI were associated with PWV (P < 0.05 for all associations, Table 2 ). Maximal viral load, viral load >10 5 copies/ml for >6 months duration, current viral load, current CD4 count, minimum CD4 count, CD4 count <200 cell/ml for >6 months, creatinine, and GGT were not associated with PWV (P > 0.1 for all associations).
The significant univariate associations of PWV with metabolic factors and HAART were adjusted for age, sex, and markers related to disease activity, using a multivariable model weighted for age which included sex, GGT, time to HIV-infection diagnosis, viral load >10 5 copies/ ml for a period >6 months, and CD4 count <200 cells/ml for >6 months. The association between PWV and diastolic blood pressure (b = 0.059, (95% CI: 0.021,0.096), P < 0. In a multivariable model, weighted for the effect of age, which included sex and all variables with P < 0.05 at univariate analysis, the independent determinants of PWV were HAART duration, cholesterol levels, and blood pressure (mean, or diastolic examined separately) ( Table 2 , P < 0.05).
diScuSSion
In this study, we have shown that "HIV-infected" patients had a higher PWV than age-and sex-matched healthy controls The values are mean ± s.d. or medians and interquartile range where applicable. ALP, alkaline phosphatase; ALT, alanine aninotransferase; AST, aspartate transaminase; DBP, diastolic blood pressure; GGT, γ-glutamyl transpeptidase; HAART, highly active antiretroviral therapy (any regimen); MBP, mean blood pressure; N/A, not applicable; NNRTI, non-nucleoside reverse transcriptase inhibitors; NRTI, nucleoside reverse transcriptase inhibitors; PI, protease inhibitor; PWV, pulse wave velocity; SBP, systolic blood pressure; viral load, patients with viral load >10 5 for >6 months duration. *P value for analysis of variance between three groups. **P value for comparison between HAART vs. non-HAART. † P = ns for PWV in HIV-infected patients on HAART versus vs. hypertensive controls.
articles "HIV-Infected" Patients and Arterial Stiffness and a lower PWV than age-and sex-matched hypertensive subjects with similar other atherosclerotic factors. However, PWV in "HIV-infected" patients undergoing HAART was increased in similar levels with the PWV of subjects suffering from untreated hypertension, an established factor for cardiovascular disease. To our knowledge, this is the first study to compare the arterial stiffness between "HIV-infected" patients and patients with untreated hypertension. Finally, in the present study, multivariate regression analysis revealed an independent association of HAART duration, serum cholesterol, and blood pressure (diastolic and mean) with PWV in "HIV-infected" patients.
In the present study, we have found that "HIV-infected" patients either under HAART or naive to antiretroviral treatment had increased PWV compared to age-and sex-matched healthy controls. This finding suggests that HIV infection per se may be related with impaired arterial wall properties. A number of studies support direct deleterious effect of HIV infection on vascular properties either through immunodepression 6, 12, 18, 19 or through low-grade inflammation 20 resulting in insulin resistance and endothelial dysfunction. More evidence arises from autopsy findings during the pre-HAART era that reported atherosclerotic lesions in HIV-infected patients, even in the absence of traditional risk factors. 21 In the present study, PWV in "HIV-infected" patients undergoing HAART was higher than the PWV in patients naive to HAART and similar with the PWV of subjects suffering from untreated hypertension. Our findings are in agreement with those of Schillaci et al. who also found that "HIV-infected" patients on HAART had a higher PWV compared to patients not receiving antiretroviral treatment. 14 Several studies have suggested a number of mechanisms through which The multivariate models are weighted for age and include all variables with P < 0.05 at univariate analysis. The DBP and MBP variables were entered in the multivariate model separately to avoid co-linearity. BMI, body mass index; DBP, diastolic blood pressure; GFR, glomerular filtration rate; GGT, γ-glutamyl transpeptidase; HAART, highly active antiretroviral therapy (any regimen); HIV, human immunodeficiency virus; MBP, mean blood pressure; NNRTI, non-nucleoside reverse transcriptase inhibitors; NRTI, nucleoside reverse transcriptase inhibitors; PI, protease inhibitor; PWV, pulse wave velocity; SBP, systolic blood pressure. a All variables with P < 0.05 at univariate analysis with the exception of GFR, retained their statistical significance after adjustment for sex, GGT, time to HIV diagnosis, viral load of over 10 5 copies/ml for a period of more than 6 months and CD4 count <200 cells/ml for 6 months to control for markers related disease activity.
articles "HIV-Infected" Patients and Arterial Stiffness antiretroviral medication induces detrimental vascular effects. In detail, HAART has been related with dyslipidemia, 22 increased diastolic blood pressure, 23, 24 the appearance of metabolic syndrome, 25 and atherosclerotic lesion formation independently of dyslipidemia. 26 In accordance with the above mechanisms, our patients receiving HAART had increased lipids, diastolic blood pressure, and PWV compared to patients naive to HAART. Furthermore, in the present study, the duration of HAART was related with increased cholesterol and triglyceride levels in HIV-infected patients and was an independent determinant of PWV. In previous studies, [13] [14] [15] time of exposure to HAART in "HIV-infected" patients was also a contributor for increased arterial stiffness. Moreover, in our study patients on HAART had a higher GGT than patients naive to HAART, though GGT levels were within normal range for all patients. This finding suggests a drug-induced stress on liver function, which may contribute to elevation of cholesterol and triglyceride levels in patients receiving HAART. 27 Thus, HAART may be linked to an increased PWV, which is similar to the PWV of untreated hypertensives, through its detrimental effects on lipids and blood pressure. 2, [5] [6] [7] [22] [23] [24] [25] [26] However, in the present study, the independent association of HAART duration with PWV in a model including lipids and blood pressure suggests that the detrimental effects of HAART on arterial wall properties may not be attributed solely to its effects on metabolic factors. In support of this hypothesis, studies have shown that HAART may promote atherosclerotic lesion formation independently of dyslipidemia by increasing CD36-dependent cholesterol accumulation in macrophages. 26 Additionally, the adverse effects of antiretroviral treatment on carotid intima-media thickness have been reported in very young HIV patients without traditional risk factors. 5 In our study, we also observed an independent association of cholesterol levels and blood pressure with PWV in "HIVinfected" patients. Increased diastolic blood pressure and lipidemia have been observed in "HIV-infected" patients. 23 Cholesterol levels and blood pressure has been also related with an increased carotid intima-media thickness in "HIVinfected" patients. 6, 7 The detrimental effects of lipids and blood pressure on arterial wall properties leading to arterial stiffening and subsequent atherosclerotic cardiovascular and cerebrovascular disease have been previously documented. 8, 9, 11 Studies have also shown that increased cholesterol levels and/or increased blood pressure may impair endothelial function 28, 29 and that endothelial dysfunction may contribute to increased arterial stiffness. 15 Thus, cholesterol and/or blood pressure induced-endothelial dysfunction may explain the close link between cholesterol levels, blood pressure, and PWV, as observed in the present study. Triglycerides were also associated with increased PWV in the HIV-infected patients of our study even after adjustment for age, sex, and disease activity parameters. However, in a model including use of HAART and HAART duration, triglycerides were not an independent determinant of PWV, likely because of their close association with use of HAART and HAART duration, as demonstrated in our study. In line with our findings, studies have shown that use of HAART, in particular of PIs, is related with twofold higher incidence rate for hypertriglyceridemia than for hypercholesterolemia. 27 Our results establish a close link between PWV, HAART duration, and metabolic factors in "HIV-infected" patients However, this case-control study was not designed to verify whether this is a causative relation or whether increased PWV and metabolic disorders are parallel effects caused by HAARTmediated and/or disease-mediated effects on inflammatory process, endothelial dysfunction, and fibrosis within arterial wall in "HIV-infected" patients. As initiation of HAART is based on indications of more severe HIV infection, our study design does not permit to fully clarify whether differences between patients with or without HAART are related to HAART per se or to disease severity and/or duration of severe HIV infection.
The relatively small number of our study population should also be acknowledged as it may not permit to study in depth all aspects of disease activity, metabolic syndrome, smoking status, and pulse pressure in relation to arterial wall properties.
Despite of the uncertainty on the contributing mechanisms to arterial stiffening in "HIV-infected" patients, we may consider the assessment of vascular indices such as PWV, because they may identify "HIV-infected" patients at risk for cardiovascular complications. 8, 9 In summary, in the present study, we have found that "HIV-infected" patients either under HAART or naive to antiretroviral treatment have increased PWV compared to healthy controls. Additionally, our study showed that "HIVinfected" patients under HAART had higher levels of PWV than naive to therapy patients and that arterial elastic properties of patients on HAART were similar to those of untreated hypertensive patients. Among "HIV-infected" patients, HAART duration, cholesterol levels, and blood pressure were independently related to increased arterial stiffness.
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